Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12110268 | 0.83 | KMT2A (0.56) | SMN1; SMN2MAPK1KMT2AHRH4KDM4E | |
| SCHEMBL9619196 | 0.83 | KDM4E (0.58) | SMN1; SMN2MAPK1KMT2AHRH4KDM4E | |
| SCHEMBL15386251 | 0.81 | MAPT (0.50) | SMN1; SMN2MAPK1KMT2AHRH4KDM4E | |
| SCHEMBL28692486 | 0.77 | HTT (0.53) | SMN1; SMN2HRH4KDM4EHTTALDH1A1 | |
| SCHEMBL15386410 | 0.77 | ALDH1A1 (0.62) | SMN1; SMN2MAPK1KMT2AKDM4EHTT | |
| SCHEMBL9066172 | 0.76 | ALDH1A1 (0.66) | SMN1; SMN2KMT2AKDM4EHTTALDH1A1 | |
| SCHEMBL17309194 | 0.75 | HRH4 (0.66) | SMN1; SMN2KMT2AHRH4KDM4EHTT | |
| SCHEMBL2689185 | 0.75 | KMT2A (0.49) | SMN1; SMN2MAPK1KMT2AHRH4KDM4E | |
| SCHEMBL912709 | 0.75 | MAPT (0.54) | SMN1; SMN2MAPK1KMT2AHRH4KDM4E | |
| SCHEMBL14641243 | 0.75 | MAPK1 (0.49) | SMN1; SMN2MAPK1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | MTOR, PIK3CA, PIK3CD | SMN1; SMN2 2486/4885MAPK1 216/4885KMT2A 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.